Targeting SHP2 Reverses BRAF Inhibitor Tolerance in Anaplastic Thyroid Carcinoma.
Tang T, Zhou J, Zhang LX, Yang G, Li WN, Zhu JJ, Xiong YF, Li JD.
Anticancer Agents Med Chem · journal article · DOI 10.2174/1871520623666230214093122 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för SHP099. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
29 hitsSHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model.
García Barberá F, Picech F, Cecenarro L, Mezger GF, Faure E, Zlocowski N, Calafat P, De Battista JC, Mukdsi JH, Sosa LDV, Petiti JP.
Neuro Oncol · research-article; journal article · DOI 10.1093/neuonc/noaf057Targeting PDGFRA-SHP2 signaling enhances radiotherapy in IDH1-mutant glioma.
Yu X, Song X, Tiek D, Wu R, Walker M, Horbinski C, Hu B, Cheng SY.
Neuro Oncol · research-article; journal article · DOI 10.1093/neuonc/noaf086Cheminformatic profiling of Azardirachta indica phytochemicals as dual SHP2/HSP90 oncogenic inhibitors: Identification of nimbocinol, nimbidinin, and margolone.
Agboola OE, Ayinla ZA, Apalowo OE, Agboola SS, Fajana OM, Ekundayo BE, Itakorode BO, Oyinloye BE.
Ann Pharm Fr · journal article · DOI 10.1016/j.pharma.2025.04.001SHP099-containing multi-targeting hydrogel promotes rapid skin reconstruction through modulating a variety of cells.
Liu Z, Chen L, Hao B, Hou Y, Lv C, Zhu Y, Han C.
Front Bioeng Biotechnol · research-article; journal article · DOI 10.3389/fbioe.2025.1564827Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth.
Bye BA, Jack JL, Pierce A, Walsh RM, Eades AE, Chalise P, Olou A, VanSaun MN.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers17071152Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway.
Hao MW, Zhang TX, Dong D, Zhou X, Gao H.
Med Oncol · journal article · DOI 10.1007/s12032-025-02683-8SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.
He C, Yu J, Mao S, Yang S, Jiang X, Huang L, Li M, He Y, Zhang X, Xiang X.
Clin Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/ctm2.70231Development of an ALK-positive Non-Small-Cell Lung Cancer in Vitro Tumor 3D Culture Model for Therapeutic Screening.
Berry MA, Bland AR, Major GS, Ashton JC.
J Histochem Cytochem · research-article; journal article · DOI 10.1369/00221554251318435Prediction of SHP2-E76K binding sites based on molecular dynamics simulation and Markov algorithm.
Zhang SP, Chen LJ, Shi ZL, Li X, Ma Y.
J Biomol Struct Dyn · journal article · DOI 10.1080/07391102.2024.2431193Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects.
Wang K, Zhang X, Hu Y, Guo J, Shen G, Zhang K, Jiang S, Wang T.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2024.117036Allosteric inhibition of the tyrosine phosphatase SHP2 enhances the anti-tumor immunity of interferon α through induction of caspase-1-mediated pyroptosis in renal cancer.
Xi R, Cao Y, Fu N, Sheng Y, Yu J, Li L, Zhang G, Wang F.
Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2024.113498The combination of SHP099 inhibits the malignant biological behavior of L-OHP/5-FU-resistant colorectal cancer cells by regulating energy metabolism reprogramming.
Wang M, Yu K, Fu W, Yang L.
Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2024.150262NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C<sup>low</sup> Monocytes/Macrophages Differentiation to Accelerate Thrombolysis.
Ying K, Xin W, Xu Y, Lv D, Zhu H, Li Y, Xu W, Yan C, Li Y, Cheng H, Chen E, Ma G, Zhang X, Ke Y.
Adv Sci (Weinh) · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/advs.202308166Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients.
Fernández DI, Diender M, Hermida-Nogueira L, Huang J, Veiras S, Henskens YMC, Te Loo MWM, Heemskerk JWM, Kuijpers MJE, García Á.
Thromb Res · journal article · DOI 10.1016/j.thromres.2023.06.001Inhibition of SHP2 by the Small Molecule Drug SHP099 Prevents Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Ye S, Zuo B, Xu L, Wu Y, Luo R, Ma L, Yao W, Chen L, Liang G, Zhang Y.
Inflammation · journal article · DOI 10.1007/s10753-023-01784-8Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion.
Li X, Halldórsdóttir HR, Weller S, Colliander A, Bak M, Kempen P, Clergeaud G, Andresen TL.
ACS Nano · research support, non-u.s. gov't; journal article · DOI 10.1021/acsnano.2c03311Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect.
Sun Z, Xu X, Lv Z, Li J, Shi T, Sun H, Sun K, Tan G, Yan W, Yang YX, Wu R, Xu J, Guo H, Jiang Q, Shi D.
J Orthop Translat · research-article; journal article · DOI 10.1016/j.jot.2022.01.001Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H, Miyamoto R, Nagashima T, Michishita M, Tamura K, Bonkobara M.
Vet Comp Oncol · journal article · DOI 10.1111/vco.12751Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2<sup>E69K</sup>.
Du S, Lu XH, Li WY, Li LP, Ma YC, Zhou L, Wu JW, Ma Y, Wang RL.
Mol Divers · journal article · DOI 10.1007/s11030-020-10179-yTherapeutic effect of the injectable thermosensitive hydrogel loaded with SHP099 on intervertebral disc degeneration.
Wang J, Huang L, Huang Y, Jiang Y, Zhang L, Feng G, Liu L.
Life Sci · journal article · DOI 10.1016/j.lfs.2020.118891Combined administration of SHP2 inhibitor SHP099 and the α7nAChR agonist PNU282987 protect mice against DSS‑induced colitis.
Xiao J, Zhang G, Gao S, Shen J, Feng H, He Z, Xu C.
Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2020.11324Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Wang S, Battigelli A, Alkekhia D, Fairman A, Antoci V, Yang W, Moore D, Shukla A.
RSC Adv · research-article; journal article · DOI 10.1039/d0ra03864dUpregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
Yue J, Liang C, Wu K, Hou Z, Wang L, Zhang C, Liu S, Yang H.
Brain Pathol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bpa.12777Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H, Kurita S, Miyamoto R, Ochiai K, Tamura K, Bonkobara M.
Vet Comp Oncol · journal article · DOI 10.1111/vco.12524Selective inhibition of leukemia-associated SHP2<sup>E69K</sup> mutant by the allosteric SHP2 inhibitor SHP099.
Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, Wu J.
Leukemia · research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41375-018-0020-5Allosteric Modulation of Phosphatase Activity May Redefine Therapeutic Value.
Salamoun JM, Wipf P.
J Med Chem · comment; journal article · DOI 10.1021/acs.jmedchem.6b01210Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J, Chen CH, Chen YN, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C, Grunenfelder D, Ho S, Kang ZB, Karki R, Kato M, Keen N, LaBonte LR, Larrow J, Lenoir F, Liu G, Liu S, Lombardo F, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Ramsey T, Sellers WR, Shultz MD, Stams T, Towler C, Wang P, Williams SL, Zhang JH, LaMarche MJ.
J Med Chem · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/acs.jmedchem.6b00680Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD.
Nature · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1038/nature18621